BLCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bausch + Lomb Corp (BLCO) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown some positive financial performance and insider buying, the lack of significant upward momentum in technical indicators, weak options sentiment, and mixed analyst ratings suggest it is better to hold off on investing right now.
The stock shows neutral to slightly bullish technical indicators. The MACD is positive but contracting, RSI is neutral at 53.934, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock has a high probability of declining in the short term (-3.55% in the next week, -8.78% in the next month).
Insiders are buying, with a significant 704.32% increase in buying activity over the last month.
Financial performance in Q4 2025 showed strong revenue growth (up 9.77% YoY) and improved net income.
Some analysts have raised price targets, with Citi and RBC Capital giving a Buy or Outperform rating.
Mixed analyst ratings, with some firms maintaining Hold or Underperform ratings.
No recent news or event-driven catalysts to drive the stock higher.
Weak options sentiment and a high probability of short-term price declines.
Continued uncertainty around Bausch Health's full separation.
In Q4 2025, the company reported revenue growth of 9.77% YoY to $1.405 billion. Net income improved significantly, up 1833.33% YoY, but remains negative at -$58 million. EPS increased to -0.16, up 1500.00% YoY. Gross margin improved to 58.08%, up 4.55% YoY.
Analyst ratings are mixed. While some firms like Citi and RBC Capital have raised price targets to $21 and $20 respectively with Buy/Outperform ratings, others like Evercore ISI and BofA maintain In Line or Underperform ratings. The average price target is slightly above the current price, but sentiment is not overwhelmingly positive.
